09/06/2026
A international trial reveals that a traditional post-heart attack treatment offers no real benefit — and actually harms many patients.
For over forty years, discharging heart attack survivors with a prescription for beta-blockers has been an unquestioned standard of care designed to lower blood pressure and ease the heart's workload.
However, the international REBOOT trial, which tracked more than 8,400 patients in Italy and Spain, has dramatically challenged this protocol. Focusing on survivors whose heart function remained relatively healthy after an attack, researchers discovered that those taking beta-blockers saw no reduction in their risk of death, subsequent heart attacks, or hospitalizations for heart failure compared to those who did not take them.
Crucially, a subgroup analysis revealed a troubling gender disparity: women with normal heart function who received beta-blockers actually faced a higher risk of adverse cardiac events, emphasizing the urgent need to transition away from one-size-fits-all prescription practices.
This shifting utility of beta-blockers is largely driven by rapid advances in modern cardiology, where swift artery-clearing procedures, powerful statins, and advanced blood thinners now perform the therapeutic heavy lifting.
While beta-blockers remain crucial for patients with heart failure or abnormal rhythms, the study urges doctors to be far more selective.
source: Ibáñez, B., Latini, R., Rossello, X., et al. Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction. New England Journal of Medicine.
